Phathom reports Q4/FY2023 results; VOQUEZNA launch nets $0.7M revenue, cash runway extended to 2026

Phathom Pharmaceuticals, Inc.

Q4 net revenue $0.7M from VOQUEZNA launch; cumulative prescriptions over 14,000 as of Feb 23, 2024.
Expanded term loan facility up to $300M with more favorable terms; access to $160M additional; cash runway through 2026.
Express Scripts added VOQUEZNA to formularies; ~60M commercial lives covered (~38% of U.S. commercial).
FDA accepted NDA for Non-Erosive GERD; PDUFA July 19, 2024; launch expected upon approval.
Net loss Q4 $79.6M ($46M non-GAAP adjusted); G&A up due to commercial build and stock-based comp.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Phathom Pharmaceuticals, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $0.7 million.

Period: the fourth quarter and full year ended December 31, 2023
Revenue: $0.7 million
Result: reported results

Exact text from the filing

Business Update • Launched VOQUEZNA ® (vonoprazan) tablets in November 2023 for the treatment of Erosive GERD (gastroesophageal reflux disease), achieving net revenues of $0.7 million for the fourth quarter • Early physician prescribing demonstrates strong demand for VOQUEZNA • Secured expanded commercial coverage for VOQUEZNA with a top U.S. pharmacy benefit

View on SEC.gov

Browse all earnings releases →

Phathom Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-061512

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.